Table 2.

Risk for HCC and Survival Among HBV-Infected Alaska Native Males Aged <40 Years and Females Aged <50 Years — Alaska, 1982–2012.

Characteristics	HCC cases in cohort	HCC incidence/1,000 person-years follow-up	RR (95% CI)	Median survival, years (range)	p-valuea	% with 5-year survivalb	p-valuec
Total	22	1.0	N/A	11.3 (0.1–30.4)	N/A	15/21 (71%)	N/A
Sex
Female	7	0.6	Ref	5.9 (1.1–24.3)	0.65	4/6 (67%)	1.0
Male	15	1.4	2.2 (0.8–6.3)	11.8 (0.1–30.4)		11/15 (73%)
Age at first HBsAg+
<10 years	15	1.5	Ref	14.2 (1.1–29.3)	0.13	12/14 (86%)	0.12
≥10 years	7	0.6	0.4 (0.1–1.1)	4.2 (0.1–30.4)		3/7 (43%)
<18 years	20	1.3	Ref	12.9 (0.1–30.4)	0.36	14/19 (74%)	0.50
≥18 years	2	0.3	0.2 (0.03–1.0)	5.0 (3.4–6.6)		1/2 (50%)
Age at HCC diagnosis
<20 years	11	--	--	17.7 (0.3–30.4)	0.06	9/11 (82%)	0.36
≥20 years	11			5.9 (0.1–27.9)		6/10 (60%)
HCC tumor staged
Early	15	--	--	14.4 (1.1–30.4)	0.01	12/14 (86%)	0.12
Late	7			4.2 (0.1–11.8)		3/7 (43%)
HBV genotype/subgenotype
A2	1	0.4	Ref	4.2	0.02f	0/1 (0%)	0.02f
B6	0	0.0		N/A		N/A
C2	0	0.0		N/A		N/A
D	2	0.2		0.2 (0.1–0.3)		0/2 (0%)
F1	19	4.4	22.8 (6.7–120)e	14.0 (1.1–30.4)		15/18 (83%)

Abbreviations: CI, confidence interval; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; N/A, not applicable; RR, risk ratio.

Notes: Statistically significant results highlighted in bold; -- indicates analysis not done.

^aLog rank test comparing median years of survival within category.

^bNumber surviving ≥5 years after HCC diagnosis; 1 person followed for <5 years after HCC diagnosis and excluded from 5-year survival analysis.

^cFishers exact test comparing % surviving ≥5 year after HCC diagnosis within category.

^dEarly-stage tumor if single tumor ≤5 cm in diameter or ≤3 tumors ≤3 cm in diameter; otherwise late-stage tumor. Tumor size unknown for persons refusing additional evaluation.

^eComparing persons with HBV genotype F with all persons with a known genotype.

^fComparing persons with HBV genotype F with persons with HBV genotype A and D.